Fig. 1 | Scientific Reports

Fig. 1

From: Low serum neopterin early indicates durable benefits of atezolizumab and pembrolizumab therapy in advanced lung cancer

Fig. 1

Neopterin concentrations at baseline (NEO.0) and at the end of the 1st, 2nd, 3rd, and 4th cycles (NEO.1–NEO.4) in NSCLC patients dosed with PD-1/PD-L1 inhibitors stratified by the long-term benefits of treatment (≥ 12 months). The results are presented as medians (markers) with interquartile ranges (whiskers). The significant differences between long-term responders and patients without durable benefits are highlighted with red asterisks. The differences in the on-treatment levels compared to baseline values for patients without benefits are shown with the connecting lines. There were no significant differences in the on-treatment NEO levels compared to baseline values in long-term responders.

Back to article page